OBJECTIVE: The aim of this study is to explore if ABCG2 is related to the grade of glioma and resistance to chemotherapeutic drug for glioma. METHODS: The ABCG2 expression and distribution among glioma tissues of different grades and other samples were examined using tissue microarray technique. The enhancement of sensitivity of CD133+ glioma stem cells to chemotherapeutic agent, mitoxantone through addition of ABCG2 competitive inhibitor nicardipine was testified by MTT assay and FACS analysis. RESULTS: The positive immunostaining of ABCG2 was observed in less than 10% of low-grade gliomas (3/31 in grade I + II) and in more than 40% of high-grade gliomas (16/37 in grade III + IV), which was statistically different (chi (2) = 10.710, P = 0.0011). In samples consisting of glioma stem cells (CD133+), the positive-straining rate was 100% (4/4), while in CD133- fraction, no positive staining was observed. A simultaneous treatment of CD133+ tumor cells with concentration-dependent mitoxantone (10(-5)-1 microM) and 2.5/5.0 microM nicardipine resulted in synergistic cytotoxicity. The apoptotic rate of CD133+ cells treated with mitoxantone plus nicardipine was significantly higher than that treated with mitoxantone alone (58.54 +/- 7.06% vs. 30.7 +/- 3.79%, P < 0.01). CONCLUSIONS: Our results showed that ABCG2 is also expressed in glioma stem cells and the expression level of ABCG2 is positively associated with the increasing pathological grade of glioma (poor cell differentiation). ABCG2 plays a key role in glioma cells resistance to mitoxantone, chemotherapeutic drug for glioma. Thus, inhibition of ABCG2 protein activity by nicardipine in glioma can sensitize it to mitoxantone, which may lead to better treatment strategies for cancers.
OBJECTIVE: The aim of this study is to explore if ABCG2 is related to the grade of glioma and resistance to chemotherapeutic drug for glioma. METHODS: The ABCG2 expression and distribution among glioma tissues of different grades and other samples were examined using tissue microarray technique. The enhancement of sensitivity of CD133+ glioma stem cells to chemotherapeutic agent, mitoxantone through addition of ABCG2 competitive inhibitor nicardipine was testified by MTT assay and FACS analysis. RESULTS: The positive immunostaining of ABCG2 was observed in less than 10% of low-grade gliomas (3/31 in grade I + II) and in more than 40% of high-grade gliomas (16/37 in grade III + IV), which was statistically different (chi (2) = 10.710, P = 0.0011). In samples consisting of glioma stem cells (CD133+), the positive-straining rate was 100% (4/4), while in CD133- fraction, no positive staining was observed. A simultaneous treatment of CD133+ tumor cells with concentration-dependent mitoxantone (10(-5)-1 microM) and 2.5/5.0 microM nicardipine resulted in synergistic cytotoxicity. The apoptotic rate of CD133+ cells treated with mitoxantone plus nicardipine was significantly higher than that treated with mitoxantone alone (58.54 +/- 7.06% vs. 30.7 +/- 3.79%, P < 0.01). CONCLUSIONS: Our results showed that ABCG2 is also expressed in glioma stem cells and the expression level of ABCG2 is positively associated with the increasing pathological grade of glioma (poor cell differentiation). ABCG2 plays a key role in glioma cells resistance to mitoxantone, chemotherapeutic drug for glioma. Thus, inhibition of ABCG2 protein activity by nicardipine in glioma can sensitize it to mitoxantone, which may lead to better treatment strategies for cancers.
Authors: L A Doyle; W Yang; L V Abruzzo; T Krogmann; Y Gao; A K Rishi; D D Ross Journal: Proc Natl Acad Sci U S A Date: 1998-12-22 Impact factor: 11.205
Authors: John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel Journal: Mol Cancer Ther Date: 2002-04 Impact factor: 6.261
Authors: Rossella Galli; Elena Binda; Ugo Orfanelli; Barbara Cipelletti; Angela Gritti; Simona De Vitis; Roberta Fiocco; Chiara Foroni; Francesco Dimeco; Angelo Vescovi Journal: Cancer Res Date: 2004-10-01 Impact factor: 12.701
Authors: Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks Journal: Nature Date: 2004-11-18 Impact factor: 49.962
Authors: Johnathan E Lawrence; Christopher J Steele; Richard A Rovin; Robert J Belton; Robert J Winn Journal: J Neurooncol Date: 2015-12-07 Impact factor: 4.130
Authors: Rajendar K Mittapalli; Alexander H Chung; Karen E Parrish; Donna Crabtree; Kyle G Halvorson; Guo Hu; William F Elmquist; Oren J Becher Journal: Mol Cancer Ther Date: 2016-02-16 Impact factor: 6.261